Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer (Q83145997)
scientific article published on 27 December 2011
Language:
(P31) (Q13442814)
(P50) (Q89808263)
(Q11718282)
(Q116996864)
(P304) 372-379
(P407) (Q1860)
(P433) 4
(P478) 30
(P577) Tuesday, December 27, 2011
(P921) (Q18936)
(Q7083106)
(Q172341)
(P1433) (Q400292)
(P1476) "Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer" (language: en)
(P2093) Stan B Kaye
Joo Ern Ang
Charlie Gourley
Beth Y Karlan
Amit Amnon
Katherine M Bell-McGuinn
Lee-May Chen
Michael Friedlander
Tamar Safra
Mark Wickens
Elizabeth S Lowe
James Carmichael
Bella Kaufman
other details
description scientific article published on 27 December 2011

External Links